The TSC1 gene provides instructions for producing a protein called hamartin. Within cells, hamartin interacts with a protein called tuberin, which is produced from the TSC2 gene. These two proteins help control cell growth and division (proliferation) and cell size. Proteins that normally prevent cells from growing and dividing too fast or in an uncontrolled way are known as tumor suppressors. Hamartin and tuberin carry out their tumor suppressor function by interacting with and regulating a wide variety of other proteins.
Health Conditions Related to Genetic Changes
TSC1 gene variants (also known as mutations) can cause a disorder called lymphangioleiomyomatosis (LAM), although variants in the TSC2 gene appear to be responsible for most cases of this disorder. This destructive lung disease is caused by the abnormal overgrowth of smooth muscle-like tissue in the lungs. It occurs almost exclusively in women, causing coughing, shortness of breath, chest pain, and lung collapse.
LAM can occur alone (isolated or sporadic LAM) or in combination with a condition called tuberous sclerosis complex (described below). Researchers suggest that sporadic LAM can be caused by a random variant in the TSC1 gene that occurs very early in development. As a result, some of the body's cells have a normal version of the gene, while others have the altered version. This situation is called mosaicism. When a variant occurs in the other copy of the TSC1 gene in certain cells during a woman's lifetime (a somatic variant), she may develop LAM.More About This Health Condition
Tuberous sclerosis complex
Hundreds of variants in the TSC1 gene have been identified in individuals with tuberous sclerosis complex, a condition characterized by developmental problems and the growth of noncancerous (benign) tumors in many parts of the body. Most of these variants involve either small deletions or insertions of DNA in the TSC1 gene. Some variants create a premature stop signal in the instructions for making hamartin.
People with TSC1-related tuberous sclerosis complex are born with one altered copy of the TSC1 gene in each cell. A TSC1 gene change prevents the cell from making functional hamartin from that copy of the gene. Enough hamartin is usually produced from the other, normal copy of the TSC1 gene to regulate cell growth effectively. For some types of tumors to develop, a second variant involving the other copy of the gene must occur in certain cells during a person's lifetime.
When both copies of the TSC1 gene are altered in a particular cell, that cell cannot produce any functional hamartin. The loss of this protein allows the cell to grow and divide in an uncontrolled way to form a tumor. A shortage of hamartin also interferes with the normal development of certain cells. In people with TSC1-related tuberous sclerosis complex, a second TSC1 gene variant typically occurs in multiple cells over an affected person's lifetime. The loss of hamartin in different types of cells disrupts normal development and leads to the growth of tumors in many different organs and tissues, leading to the signs and symptoms of tuberous sclerosis complex.More About This Health Condition
MedlinePlus Genetics provides information about CholangiocarcinomaMore About This Health Condition
Inherited variants in the TSC1 gene can cause a disorder known as focal cortical dysplasia of Taylor balloon cell type. This disorder involves malformations of the cerebrum, the large, frontal part of the brain that is responsible for thinking and learning. Focal cortical dysplasia causes severe recurrent seizures (epilepsy) in affected individuals.
Other Names for This Gene
- tuberous sclerosis 1
Additional Information & Resources
Tests Listed in the Genetic Testing Registry
Scientific Articles on PubMed
- Mallela K, Kumar A. Role of TSC1 in physiology and diseases. Mol Cell Biochem. 2021 Jun;476(6):2269-2282. doi: 10.1007/s11010-021-04088-3. Epub 2021 Feb 11. Citation on PubMed
- Martignoni G, Pea M, Reghellin D, Gobbo S, Zamboni G, Chilosi M, Bonetti F. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med. 2010 Jan;134(1):33-40. doi: 10.5858/2008-0542-RAR1.1. Citation on PubMed
- Meng Y, Yu C, Chen M, Yu X, Sun M, Yan H, Zhao W, Yu S. Mutation landscape of TSC1/TSC2 in Chinese patients with tuberous sclerosis complex. J Hum Genet. 2021 Mar;66(3):227-236. doi: 10.1038/s10038-020-00839-0. Epub 2020 Sep 11. Citation on PubMed
- Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous Sclerosis Complex. 1999 Jul 13 [updated 2021 Dec 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from http://www.ncbi.nlm.nih.gov/books/NBK1220/ Citation on PubMed
- Ramlaul K, Fu W, Li H, de Martin Garrido N, He L, Trivedi M, Cui W, Aylett CHS, Wu G. Architecture of the Tuberous Sclerosis Protein Complex. J Mol Biol. 2021 Jan 22;433(2):166743. doi: 10.1016/j.jmb.2020.166743. Epub 2020 Dec 8. Citation on PubMed
- Tian X, Glass JE, Kwiatkowski DJ, Towbin AJ, Li Y, Sund KL, Krueger DA, Franz DN, McCormack FX, Gupta N. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. Ann Am Thorac Soc. 2021 May;18(5):815-819. doi: 10.1513/AnnalsATS.202008-911OC. Citation on PubMed